Tanaka et al. tested trametinib or the RAF/MEK inhibitor CH5126766 (RO5126766) (38 in Figure 5) on five NB cell lines (HP134, IMR5, NB69, NLF, SK-N-A, used as wild-type or after genetic profile mutation). This evidence concerns the gene RAF1 and neuroblastoma.